Home Study Programs

To help you obtain continuing education credit as conveniently as possible, NJPhA provides an ongoing and expanding collection of coursework that can be completed from home. As indicated below, some programs are available to NJPhA members only.

If you have any questions about the home study programs, please contact the office.

Important credit information

Please note: If you completed the home study when the original issue of the journal was released, you can not obtain credit for completing it again online. Credit issued to an individual by the course UAN number once.  Please carefully review your   education record on CPE Monitor before enrolling in a home study program.

Help Us to Help You

Support NJPhA PAC

Learn How

NJPhA Benefits

Education, news, networking & more

Get the Details

You Have Enough CE Credits

But are they the right ones?

Check Here

Immunization Update 2020: Addressing Vaccine Hesitancy in the Time of COVID-19

Mary Bridgeman, PharmD, BCPS, BCGP, FNAP

**The authors have no financial or other relevant relationships to disclose.

Audience

  • Pharmacists
  • Pharmacy Technicians

Credit

  • Contact hours: 2.0 (0.2 CEU)
  • UAN: 0136-0000-21-001-H06-P/T

Release Date: January 8, 2021  Expiration Date: January 8, 2024

Activity Type: Knowledge-based

At the completion of this activity, pharmacists will be able to:

  1. Identify changes to the immunization schedule in both
    pediatrics and adults for 2020-2021
  2. Examine CDC surveillance data for the 2020-2021 influenza season
  3. Distinguish between the monitoring parameters and adverse reactions associated with each vaccine
  4. Explain factors influencing vaccine hesitance and strategies for promoting vaccine acceptance
  5. Identify the various resources available to pharmacists for immunization information

At the completion of this activity, pharmacy technicians will be able to:

  1. Distinguish pediatric vaccines versus adult vaccine
    formulations
  2. Identify new vaccine formulations available in the U.S.
  3. Recognize where immunization recommendations can be found
  4. List reasons for vaccine hesitancy among patients
  5. Define appropriate storage requirements for vaccines

Impact of compounded sterile preparation batching frequency on pharmacy department cost and service

Rahul Jacob, PharmD; Heather DeSanto, PharmD

**The authors have no financial or other relevant relationships to disclose.

(Members, free. Nonmembers, $15.)

Members must log in to obtain the members fee. Not a member? Join the Association

Audience

  • Pharmacists

Credit

  • Contact hours: 1.0 (0.1 CEU)
  • UAN: 0136-0000-20-017-H07-P

Release Date: August 5, 2020  Expiration Date: August 5, 2023

Activity Type: Knowledge-based

At the completion of this activity, pharmacists will be able to:

  1. Define the term of "batching" compounded sterile products (CSPs)
  2. Identify different factors that can alter the intended use of dispensed IV compounded sterile products (CSPs)
  3. Analyze changes to the batching process and its impact on pharmacy services

Possible case of Morgellons disease in an acute care inpatient psychiatric hospital

Nicole M. Daniels, PharmD

**The author has no financial or other relevant relationships to disclose.

(Members, free. Nonmembers, $15.)

Members must log in to obtain the members fee. Not a member? Join the Association

Audience

  • Pharmacists

Credit

  • Contact hours: 1.0 (0.1 CEU)
  • UAN: 0136-0000-20-012-H01-P

Release Date: May 25, 2020  Expiration Date: May 25, 2023

Activity Type: Knowledge-based

Goal

Morgellons disease is a controversial condition lacking clear etiology, diagnostic criteria or treatment guidelines. This case report aims to contribute to the literature surrounding this sequelae of symptoms.

At the completion of this activity, pharmacists will be able to:

  1. Describe the clinical presentation associated with Morgellons disease (MD)
  2. Identify potential pharmacological treatment options for MD

National COVID-19 Survey: Prescription Drug Supply, Disease Transmission, and Pharmacist Intervention

Julie Kalabalik-Hoganson PharmD, BCPS, BCCCP*; Krista Jenkins PhD; Banibrata Roy P.Stat., PhD, M.Phil., M.Sc.

**The author has no financial or other relevant relationships to disclose.

(Members, free. Nonmembers, $15.)

Members must log in to obtain the members fee. Not a member? Join the Association

Audience

  • Pharmacists

Credit

  • Contact hours: 1.0 (0.1 CEU)
  • UAN: 0136-0000-21-011-H01-P

Release Date: April 12, 2021 Expiration Date: April 12, 2024

Activity Type: Knowledge-based

Goal

Provide updates and results from national survey regarding COVID-19 COVID-19 drug supply, disease transmission, and pharmacist intervention

At the completion of this activity, pharmacists will be able to:

  1. Describe the results of a national survey of Americans’ perception of the impact of COVID-19 on the prescription drug supply
  2. Explain national survey results with regards to Americans’ perception of how the SARS-CoV-2 virus is transmitted.
  3. Discuss the likelihood of Americans to receive the coronavirus vaccine, receive COVID-19 testing at a pharmacy, and to be initiated on COVID-19 treatment by a pharmacist

Evaluation of a Layered Learning Practice Model Workshop

Nicole Ryba, PharmD, BCPP, BCGP

**The author has no financial or other relevant relationships to disclose. (Members, free. Nonmembers, $15.) Members must log in to obtain the members fee. Not a member? Join the Association
Audience
  • Pharmacists
Credit
  • Contact hours: 1.0 (0.1 CEU)
  • UAN: 0136-0000-20-041-H04-P
Release Date: December 8, 2020  Expiration Date: December 8, 2023 Activity Type: Knowledge-based
Goal Provide pharmacists an overview of a Layered Learning Practice Model and evaluate the benefits of the implementation of such a model.

At the completion of this activity, pharmacists will be able to:

  1. Define the layered learning practice model
  2. Describe the benefits of utilizing the layered learning practice model

Systemic Lupus Erythematosus: A Brief Primer on Ethnic and Genetic Risk Associations

Aniya Mazyck Pharm.D., Otito Frances Iwuchukwu RPh,

**The author has no financial or other relevant relationships to disclose.

(Members, free. Nonmembers, $15.)

Members must log in to obtain the members fee. Not a member? Join the Association

Audience

  • Pharmacists
  • Pharmacy Technician

Credit

  • Contact hours: 1.0 (0.1 CEU)
  • UAN: 0136-0000-20-019-H01-P

Release Date: August 21, 2020  Expiration Date: August 21, 2023

Activity Type: Knowledge-based

After participating in this activity, the participant shall be able to:
Pharmacist: 

  • Identify the causes of Systemic Lupus Erythematosus (SLE).
  • Describe the genetic factors associated with SLE development.
  • Discuss treatment options for SLE.

Pharmacy Technicians:

  • Identify the causes of Systemic Lupus Erythematosus (SLE).
  • Discuss treatment options for SLE.D

Update on Lipid Management: American Association of Clinical Endocrinologists Hyperlipidemia Guidelines 2017

Dhara D. Shah, PharmD; Christine Lam, PharmD, BCPS, CDE, BCACP

**The authors have no financial or other relevant relationships to disclose.

(Members, free. Nonmembers, $15.)

Members must log in to obtain the members fee. Not a member? Join the Association

Audience

  • Pharmacists
  • Pharmacy Technicians

Credit

  • Contact hours: 1.0 (0.1 CEU)
  • UAN: 0136-0000-18-029-H04-P
  • UAN: 0136-0000-18-029-H04-T

Release Date: August 15, 2018  Expiration Date: August 15, 2021

Activity Type: Knowledge-based

Goal

This paper aims to update pharmacists on the newly developed American Association of Clinical Endocrinologists (AACE) guidelines for management of hyperlipidemia to provide a practical guide for endocrinologists to reduce the risks and consequences of dyslipidemia

At the completion of this activity, pharmacists will be able to:

  1. Describe the change from the Four Statin Benefit Groups to ASCVD Risk Categories
  2. Apply the shift towards treat-to-target LDL-C levels based on recent evidence based medicine
  3. Relate the differences in the risk calculator utilized in the updated guidelines compared to previous guidelines to determine the 10-year ASCVD risk
  4. Explain the place in therapy for biomarkers and its association with coronary atherosclerosis

At the completion of this activity, the pharmacy technician will be able to:

  1. Name the change from the Four Statin Benefit Groups to ASCVD Risk Categories
  2. Identify the shift towards treat-to-target LDL-C levels
  3. List the differences in the previous and updated risk calculators for a patient’s 10-year ASCVD risk

Medical Cannabis; What Pharmacists Need to Know

*Mary Bridgeman, PharmD; John L. Colaizzi, PhD; Rebecca Kim, PharmD; Daniel Li, PharmD Candidate 2023;

**The authors have no financial or other relevant relationships to disclose.

(Members, free. Nonmembers, $15.)

Members must log in to obtain the members fee. Not a member? Join the Association

Audience

  • Pharmacists

Credit

  • Contact hours: 1.0 (0.1 CEU)
  • UAN: 0136-0000-20-030-H01-P

Release Date: September 17, 2020  Expiration Date: September 17, 2023

Activity Type: Knowledge-based

Goal

In this activity, the authors present an overview of medical cannabis history, terminology, and regulation as an introduction for the pharmacy professional. Additionally, discussion of the impact of the availability of medical cannabis in New Jersey and exploration of the role of the pharmacist in assisting patients navigate cannabis use will be explored.

At the completion of this activity, pharmacists will be able to:

  • Distinguish differences in the terminology related to cannabis, including hemp, marijuana, cannabidiol, and tetrahydrocannabinol (THC)
  • Recognize the pharmacology, potential medical uses, and adverse effects of cannabis and cannabinoids
  • Identify United States (U.S.) Food and Drug Administration (FDA) approved products related to cannabis
  • Explain the history of federal and state regulatory status of medical cannabis, including approved medical indications for use in New Jersey
  • Describe the pharmacist’s role in educating patients on medical use of cannabis and cannabidiol (CBD)

NJPhA Task Force: Opioid Abuse Treatment & Prevention Summary

Report Summary Compiled by Carmela Silvestri, PharmD, CCP from the work of the NJPhA Task Force on Opioid Addicition

**The authors have no financial or other relevant relationships to disclose.

(Members, free. Nonmembers, $15.)

Members must log in to obtain the members fee. Not a member? Join the Association

Audience

  • Pharmacists
  • Pharmacy Technicians

Credit

  • Contact hours: 1.0 (0.1 CEU)
  • UAN: 0136-0000-19-008-H01-P
  • UAN: 0136-0000-19-008-H01-T

Release Date: February 27, 2019  Expiration Date: February 27, 2022

Activity Type: Knowledge-based

Goal

This activity explores the research findings of the NJPhA task force on Opioid Addiction Prevention and Treatment.  The summary aims to provide pharmacists and technicians with an overview of the opioid epidemic in a variety of practice settings and provide tools for pharmacists and technicians in combating the opioid epidemic.

At the completion of this activity, pharmacists will be able to:

  • Identify parts of the brain that are responsible for different aspects of opioid abuse
  • Explain tools, practices, and policies to prevent opioid medication diversion and reallocation
  • Describe abuse resistant drug formulations and list some of the formulations available
  • Explain medication assisted treatment (MAT) for opioid use disorder (OUD)

At the completion of this activity, technicians will be able to:

  • List elements of a fraudulent prescription
  • Identify abuse resistant drug formulations
  • Identify patients that may be victims of the opioid epidemic in a community pharmacy
  • List methods of opioid disposal

The Pathophysiology, Treatment, and Preventive Approaches in Herpes-zoster Infection

Matthew Milone, PharmD/MBA Candidate Class of 2020; *Malgorzata Slugocki, PharmD, BCPS,

**The authors have no financial or other relevant relationships to disclose.

(Members, free. Nonmembers, $15.)

Members must log in to obtain the members fee. Not a member? Join the Association

Audience

  • Pharmacists

Credit

  • Contact hours: 1.0 (0.1 CEU)
  • UAN: 0136-0000-20-031-H01-P

Release Date: September 17, 2020  Expiration Date: September 17, 2023

Activity Type: Knowledge-based

Goal

Herpes-zoster infection incidence is growing and affects millions of individuals worldwide, leading to
potentially debilitating complications. This review article is relevant to pharmacists in all areas of
practice, as it presents an overview of pathophysiology, treatment, and preventive approaches to herpes
zoster infection. Additionally, it provides a review on the newly approved Shingrix vaccine. It also sheds
light on the issue of continued backorder of the vaccine, and how to handle it, which remains an ongoing
problem. This concept is especially valuable to pharmacists practicing in the community setting.

At the completion of this activity, pharmacists will be able to:

  • Understand the pathophysiology of herpes zoster infection
  • Describe the typical clinical presentation of patients with herpes zoster
  • Define available treatment approaches
  • Describe the trials that led to Shingrix approval as well as current guidelines for administration
  • Compare Zostavax and Shingrix vaccines
  • Identify strategies on how to handle a Shingrix vaccine backorder

New Drug Update: Delafloxacin (BaxdelaTM) for Acute Bacterial Skin & Skin Structure Infections

Aamer Attaar, PharmD Candidate 2018; Marc Sturgill, PharmD 

**The authors have no financial or other relevant relationships to disclose.

(Members, free. Nonmembers, $15.)

Members must log in to obtain the members fee. Not a member? Join the Association

Audience

  • Pharmacists
  • Pharmacy Technicians

Credit

  • Contact hours: 1.0 (0.1 CEU)
  • UAN: 0136-0000-18-021-H04-P
  • UAN: 0136-0000-18-021-H04-T

Release Date: May 25, 2018  Expiration Date: May 25, 2021

Activity Type: Knowledge-based

Goal

This paper aims to update pharmacists on the use of delafloxacin in treating acute bacterial and skin structural infections.

At the completion of this activity, pharmacists will be able to:

  • Recall specific characteristics of delafloxacin including mechanism of action, dosing, spectrum of coverage, adverse effects, and therapeutic use
  • Analyze and interpret clinical trial data for delafloxacin as it relates to clinical relevance and pharmacokinetics

At the completion of this activity, technicians will be able to:

  • Recall dosing, frequency, and duration of delafloxacin administration
  • Recognize specific compounding and storage instructions for delafloxacin

Nutrition Support in a Patient With Bechet's Disease

Maria Leibfried, BS, PharmD, BCNSP; Andro Youssef, PharmD


**The authors have no financial or other relevant relationships to disclose.

(Members, free. Nonmembers, $15.)

Members must login in to obtain the members fee. Not a member? Join the Association.

Audience
  • Pharmacists
Credit
  • Contact hours: 1.0 (0.1 CEU)
  • UAN: 0136-0000-19-026-H01-P
 
Release Date: September 5, 2019 Expiration Date: September 5, 2022

 

 

 

Activity Type: Knowledge-based

 

 

Goal: The purpose of this assessment is to inform pharmacists about ways to support the nutritional needs of patients with Bechet's Disease

Objectives

At the completion of this activity, pharmacists will be able to:

  • Identify complications of Behcet's disease
  •  List challenges in providing nutrition to a patient with Behcet's disease
  • Describe why parenteral nutrition may be indicated in patients with Behcet's disease

Current and Emerging Therapies of Recurrent Clostridium Difficile Infection: A Review of the Literature

Nicole L. Ryba, PharmD, BCPP, BCGP; Jesse B. Sullivan, PharmD, BCPS, BCCCP; Joseph Cavanaugh, PharmD, BCPS, BCCCP; Jessica Hill, PharmD, BCPS, BCACP


**The authors have no financial or other relevant relationships to disclose.

(Members, free. Nonmembers, $15.)

Members must login in to obtain the members fee. Not a member? Join the Association.

Audience
  • Pharmacists
  • Pharmacy Technicians
Credit
  • Contact hours: 1.0 (0.1 CEU)
  • UAN: 0136-0000-18-038-H01-P
  • UAN: 0136-0000-18-038-H01-T
 
Release Date: November 30, 2018 Expiration Date: November 30, 2021

 

 

 

Activity Type: Knowledge-based

 

 

Goal: The purpose of this assessment is to inform healthcare professionals and allied health professionals of current and emerging therapies for recurrent Clostridium Difficile Infection as chronicled in recent medical research literature.

Objectives

At the completion of this activity, pharmacists will be able to:

  • Define recurrent C. difficile infection (CDI)
  • Describe guideline recommendations for primary CDI
  • Describe guideline recommendations for recurrence of CDI
  • Identify and Evaluate other emerging therapies for recurrent CDI

At the completion of this activity, pharmacist technicians will be able to:

 

  • Identify first line treatment options for Clostridium difficile infection
  • Describe appropriate dose of treatments options
  • Describe appropriate formulation of treatment options

The New Jersey Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Proof of participation will be submitted to mycpemonitor.net within 60 days subject to documented attendance and completion of online evaluation materials.